Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biktarvy
Pharma
Gilead's single-tablet HIV combo passes 2nd late-stage test
With the investigational product, Gilead is targeting certain segments of the HIV market who are underserved by current options.
Eric Sagonowsky
Dec 16, 2025 9:15am
Gilead's bictegravir, lenacapavir tablet meets mark in phase 3
Nov 13, 2025 9:55am
Gilead lifts guidance on PrEP launch despite cell therapy woes
Oct 31, 2025 11:51am
Gilead inks Biktarvy settlements with 3 generic drug makers
Oct 7, 2025 7:40am
Potential US budget cuts have limited impact on Gilead: analysts
Mar 26, 2025 2:47pm
ICER calls out drugmakers over 'unsupported' price hikes
Dec 12, 2024 2:24pm
